<div id="readability-page-1"><div> <p>SH PHARMA (02607.HK)<span> </span><span> +0.100 (+0.862%)  </span> <span> Short selling $1.88M; Ratio 9.207%  </span>  announced that in 1Q26, operating revenue reached RMB75.262 billion, up 6.36% YoY. Among which, pharmaceutical manufacturing sales revenue was RMB6.806 billion, up 15.64% YoY; pharmaceutical distribution sales revenue was RMB68.456 billion, up 5.52% YoY.<br/></p><br/>During the period, net profit attributable to shareholders of the listed company amounted to RMB1.418 billion, up 6.35% YoY. Basic EPS was RMB0.3823. The industrial segment contributed RMB0.66 billion in profit, while the commercial segment contributed RMB0.834 billion. Major associates contributed RMB56 million in profit. After deducting non-recurring gains and losses, attributable net profit was RMB1.238 billion, down 2.02% YoY.<p>During the period, the companys R&amp;D investment totaled RMB0.577 billion, accounting for 8.47% of industrial sales. Of which, R&amp;D expenses were RMB0.468 billion, representing 6.88% of industrial sales. (ss/u)(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-04-29 16:25.)</p><p>This article was automatically translated by AI, the Chinese version should be considered the authoritative version. AASTOCKS.com Limited does not guarantee its accuracy or completeness and accepts no liability for any damages or losses arising from the use of this translation.</p><p>AASTOCKS Financial News</p> </div></div>

601607

02607

512010

<p>SH PHARMAreported a 6.35% year-on-year increase in attributable net profit for 1Q26, reaching RMB1.418 billion. Operating revenue rose 6.36% to RMB75.262 billion, with pharmaceutical manufacturing sales up 15.64% and distribution sales up 5.52%. Basic EPS was RMB0.3823. R&D investment totaled RMB0.577 billion, accounting for 8.47% of industrial sales. After adjusting for non-recurring items, net profit was RMB1.238 billion, down 2.02% YoY. The company’s stock rose by 0.862%.</p>

AASTOCKS News

Shanghai Pharma

SH PHARMA

E Fund CSI 300 Health Care ETF

ChinaAMC SSE STAR Biology and Medicine ETF

Guotai SSE STAR Brand Name Drug ETF

Yinhua CSI Innovative Drugs Industry ETF

Penghua SSE STAR Biology and Medicine ETF

Guotai CSI Bio-medicine ETF

ChinaAMC SSE Health Care ETF Initiating Fund

Ping An CSI Medicine and Medical Device Innovation ETF

GF CSI HK Innovative Drugs Industry ETF(QDII)

E Fund Hang Seng SCHK Innovative Drug ETF

ICBCCS SSE STAR Biology and Medicine ETF

Bosera Hang Seng SCHK Innovative Drug Select ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

SH PHARMA  1Q26 Attributable Net Profit Up 6.35% YoY